Michelle Pratt
Psychiatric/Mental Health · Madison, ALNPI 1376968495
Payments from drug & device makers
Across 672 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$893
- Otsuka America Pharmaceutical, Inc.$722
- Corium, LLC$704
- plus $6K from 26 others
What the payments were for
- Food & beverage$13,01299%
- Education$1611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 104 | $1,739 |
| Alkermes, Inc. | 76 | $1,616 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,353 |
| Teva Pharmaceuticals USA, Inc. | 41 | $893 |
| Otsuka America Pharmaceutical, Inc. | 35 | $722 |
| Corium, LLC | 35 | $704 |
| Neurocrine Biosciences, Inc. | 29 | $697 |
| Bausch Health US, LLC | 34 | $630 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $600 |
| Johnson & Johnson | 28 | $563 |
| Axsome Therapeutics, Inc. | 29 | $476 |
| Vanda Pharmaceuticals Inc. | 21 | $449 |
| UCB, Inc. | 13 | $424 |
| Almatica Pharma LLC | 18 | $365 |
| Lundbeck LLC | 17 | $342 |
| Indivior Inc. | 12 | $259 |
| Supernus Pharmaceuticals, Inc. | 11 | $228 |
| Neos Therapeutics, LP | 9 | $163 |
| Harmony Biosciences LLC | 3 | $116 |
| Ironshore Pharmaceuticals Inc. | 6 | $111 |
| Idorsia Pharmaceuticals US Inc | 7 | $109 |
| Tris Pharma Inc | 7 | $106 |
| Jazz Pharmaceuticals Inc. | 5 | $105 |
| Eisai Inc. | 7 | $103 |
| Sunovion Pharmaceuticals Inc. | 4 | $66 |
| Avanir Pharmaceuticals, Inc. | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Novartis | 1 | $35 |
| Merck | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
How this compares
$13,172 in reported general payments places this provider in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 44 | $292,825 |
| RexultiBrexpiprazole | 24 | $57,472 |
| VraylarCariprazine Hcl | 36 | $52,235 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $45,978 |
| TrintellixVortioxetine Hydrobromide | 27 | $16,343 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $3,715 |
| Quetiapine Fumarate | 190 | $3,002 |
| Divalproex Sodium ErDivalproex Sodium | 42 | $2,993 |
| Trazodone Hcl | 219 | $2,796 |
| Buspirone Hcl | 143 | $2,663 |
| Bupropion XlBupropion Hcl | 129 | $2,570 |
| Aripiprazole | 82 | $2,415 |
| Duloxetine Hcl | 142 | $2,372 |
| Ziprasidone Hcl | 38 | $1,729 |
| Lamotrigine | 125 | $1,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $893 | $292,82544 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $722 | $57,47224 claims |
| AbbVieVraylar | $1,739 | $52,23536 claims |
| Alkermes, Inc.Lybalvi | $1,616 | $45,97828 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $600 | $16,34327 claims |
| Almatica Pharma LLCSertraline Hcl | $365 | $660121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Madison
- Keith WattsMadison$13K
- Stephanie KitchenMadison$9K
- Stephanie McLaughlinMadison$8K
- William CrainMadison$7K
- Lauren RossMadison$7K
- Angela WaldropMadison$6K
- Kelly GreerMadison$6K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.